Keenova’s 2Q26 results outline growth potential and long-term value prospects for MNK
Aug 11, 2026, 6:36 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The update signals stronger brand performance (Acthar/XIAFLEX) and meaningful synergy progress, plus a clearer path to a NYSE listing, which could unlock value and support a higher multiple over time. The Percocet divestiture reduces opioid exposure risk, potentially de-risking the asset mix. Near-term concerns include impairment costs and higher debt from the merger, but the updated growth guidance and pipeline milestones provide a constructive floor.
AI summary
What happened, with direct paths to the underlying reporting
Keenova reported a solid quarter led by Acthar Gel and XIAFLEX contributions, raising full-year Acthar Gel growth guidance to 20-22% and XIAFLEX to high single-digits. Positive Phase 3 data for plantar fibromatosis supports a fourth-quarter sBLA submission, with hammer toe Phase 3 enrollment slated for Q3 2026. The company also affirmed merger synergies and a 2027 NYSE listing, while divesting Percocet and absorbing Endo costs, shaping a long-term path for value realization that could influence MNK holders through improved brand momentum and structural clarity.
XIAFLEX plantar fibromatosis topline positive; sBLA submission planned in Q4 2026; hammer toe Phase 3 starts Q3 2026.
Percocet divestiture completed; impairment and Endo costs weighed on the quarter.
Synergy progress: $25m realized in Q2; on track for $100m in 2026 and $150m run-rate.
NYSE listing targeted for 2027; 2026 guidance updated: Acthar Gel +20-22% YoY; XIAFLEX high single-digits.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Mallinckrodt and Endo announce a $7 billion merger. The merger aims for increased financial flexibility and synergies. Post-merger entity will be listed on the NYSE.
